Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Taps Dotmatics Platform for Neuroscience Drug Discovery

Premium

Dotmatics said this week that AstraZeneca's Neuroscience Innovative Medicines Unit has selected its platform to manage research data associated with its collaborative drug discovery efforts.

Dotmatics platform will provide a single point of access to all data and functions for AstraZeneca and its partners, the company said. These users will have access to compound registration and tracking tools, biological screening, DMPK analysis, as well as a fully integrated chemistry and biology electronic laboratory notebook and project management capabilities.

The financial details of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.